Sulfamethoxazole

Generic Name: Sulfamethoxazole

Brand Names: Bactrim, Septra, Sulfatrim

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₁N_₃O_₃S

CAS Number: 723-46-6

Unique Ingredient Identifier: JE42381TNV

Background: Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.

Indication: Sulfamethoxazole is indicated in combination with trimethoprim, in various formulations, for the following infections caused by bacteria with documented susceptibility: urinary tract infections, acute otitis media in pediatric patients (when clinically indicated), acute exacerbations of chronic bronchitis in adults, enteritis caused by susceptible Shigella, prophylaxis and treatment of Pneumocystis jiroveci pneumonia, and travelers' diarrhea caused by enterotoxigenic E. coli.

In Canada, additional indications include the adjunctive treatment of cholera, treatment of bacillary dysentery, nocardiosis, and second-line treatment of brucellosis in combination with gentamicin or rifampicin.

Associated Conditions: Acute Exacerbation of Chronic Bronchitis (AECB) caused by susceptible bacteria, Acute Otitis Media caused by susceptible bacteria, Brucellosis, Dysentery, Bacillary, Nocardiosis, Pneumocystis Jirovecii Pneumonia, Urinary Tract Infection caused by susceptible bacteria, Susceptible Cholera, Susceptible Enteritis infectious caused by Shigella flexneri, Susceptible Enteritis infectious caused by Shigella sonnei, Susceptible Travelers' Diarrhea caused by Enterotoxigenic E. Coli (ETEC) Infection

Clinical Trials

Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis

Phase 4

Recruiting

Conditions: Cystectomy
Bladder Cancer Requiring Cystectomy
Postoperative Infections
Antibiotic Prophylaxis
Ileal Conduit

Interventions: Drug: Pivmecillinam
Drug: Amoxicillin clavulanic acid
Drug: Amoxicillin
Drug: Cefuroxime
Drug: Ciprofloxacin
Drug: Linezolid
Drug: Nitrofurantoin
Drug: Trimethoprim
Drug: Sulfamethoxazole trimethoprim
Drug: Fluconazole

First Posted Date: 2024-11-29

Last Posted Date: 2025-01-09

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 248

Registration Number: NCT06709196

Locations: 🇩🇰
Department of Urology, Aalborg University Hospital, Aalborg, Denmark
🇩🇰
Department of Urology, Aarhus University Hospital, Aarhus, Denmark
🇩🇰
Department of Urology, Rigshospitalet, Copenhagen, Denmark

and more 2 locations

Assessing the Utility of Prophylactic Antibiotics at Time of Urethral Bulking Using Bulkamid (Bulkamid Study)

Phase 4

Not yet recruiting

Conditions: Stress Urinary Incontinence

Interventions: Drug: Bactrim or Macrobid
Drug: Placebo

First Posted Date: 2024-11-26

Last Posted Date: 2025-01-15

Lead Sponsor: Ohio State University

Target Recruit Count: 138

Registration Number: NCT06706362

Locations: 🇺🇸
The Ohio State University Wexner Medical Center OB/GYN Female Pelvic Medicine and Reconstructive Surgery, Columbus, Ohio, United States

Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy

Not Applicable

Recruiting

Conditions: Biliary Atresia
Anti-Bacterial Agents
Cholangitis

First Posted Date: 2023-06-29

Last Posted Date: 2024-10-21

Lead Sponsor: Children's Hospital of Fudan University

Target Recruit Count: 356

Registration Number: NCT05925309

Locations: 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China

Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

Phase 4

Recruiting

Conditions: Endocarditis Infective

First Posted Date: 2022-06-01

Last Posted Date: 2025-03-11

Lead Sponsor: Fundacion Clinic per a la Recerca Biomédica

Target Recruit Count: 360

Registration Number: NCT05398679

Locations: 🇪🇸
Hospital Virgen de la Macarena, Sevilla, Andalucía, Spain
🇪🇸
Hospital Virgen del Rocío, Sevilla, Andalucía, Spain
🇪🇸
Parc Taulí Hospital Universitari, Sabadell, Barcelona, Spain

and more 17 locations

Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome

Phase 1

Recruiting

Conditions: Short Bowel Syndrome
Infection, Bacterial

Interventions: Drug: Levofloxacin
Drug: Sulfamethoxazole trimethoprim
Drug: Ofloxacin
Drug: Amoxicillin

First Posted Date: 2022-03-31

Last Posted Date: 2024-08-29

Lead Sponsor: Central Hospital, Nancy, France

Target Recruit Count: 10

Registration Number: NCT05302531

Locations: 🇫🇷
CHRU Nancy, Vandœuvre-lès-Nancy, Lorraine, France

Role of Prophylactic Postoperative Antibiotics in HoLEP

Phase 4

Conditions: Urinary Tract Infections
Benign Prostatic Hyperplasia

Interventions: Procedure: Holmium Laser Enucleation of prostate
Drug: Nitrofurantoin
Drug: Cephalexin
Drug: Sulfamethoxazole Trimethoprim Combination
Drug: Ciprofloxacin

First Posted Date: 2022-03-10

Last Posted Date: 2022-03-11

Lead Sponsor: Baylor Research Institute

Target Recruit Count: 100

Registration Number: NCT05274672

Locations: 🇺🇸
Einstein Healthcare network, Philadelphia, Pennsylvania, United States
🇺🇸
Baylor Scott and White, Temple, Texas, United States

Collaborative Urological Prosthetics Investigation Directive Research Group

Early Phase 1

Active, not recruiting

Conditions: Erectile Dysfunction
Penile Prosthesis Infection

Interventions: Drug: Doxycycline
Drug: Ciprofloxacin
Drug: Augmentin
Drug: Bactrim

First Posted Date: 2021-10-29

Last Posted Date: 2025-03-10

Lead Sponsor: University of Chicago

Target Recruit Count: 800

Registration Number: NCT05100654

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Or v IV Antibiotics for Infection

Phase 3

Conditions: Joint Infection

Interventions: Drug: Bactrim
Drug: Cefadroxil
Drug: Doxycycline Hcl
Drug: Clindamycin

First Posted Date: 2021-01-26

Last Posted Date: 2021-01-26

Lead Sponsor: Rothman Institute Orthopaedics

Target Recruit Count: 308

Registration Number: NCT04723940

Locations: 🇺🇸
Rothman Orthopaedic Institute, Philadelphia, Pennsylvania, United States

Effect of Antibiotics on Urinary Microbiome

Early Phase 1

Withdrawn

Conditions: Microtia
UTI
Antibiotics Causing Adverse Effects in Therapeutic Use
Antibiotic Resistant Infection
Bacteriuria

Interventions: Drug: Placebo oral tablet
Drug: Bactrim DS 800Mg-160Mg Tablet

First Posted Date: 2020-01-18

Last Posted Date: 2021-11-03

Lead Sponsor: Johns Hopkins University

Registration Number: NCT04230746

A Non-Interventional Safety Study of Balsamic Bactrim

Completed

Conditions: Bronchitis

Interventions: Drug: Guaifenesin
Drug: Sulfamethoxazole
Drug: Trimethoprim

First Posted Date: 2016-09-16

Last Posted Date: 2017-11-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 52

Registration Number: NCT02902640

Locations: 🇵🇪
Clinica San Borja; Instituto de Enfermedades Respiratorias EFEH, Lima, Peru
🇵🇪
Clinica de Especialidades Medicas, Lima, Peru
🇵🇪
Centro de Investigaciones Medicas/Hospital Maria Auxiliadora, San Juan de Miraflores, Peru

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy